Therapeutic vaccine strategies in cancer: advances, challenges, and future directions

Abstract

Driven by recent scientific breakthroughs that underscore the critical role of the immune system in tumor development, strategies targeting the immune system have emerged as a promising avenue for cancer therapy. Therapeutic vaccine strategies represent a dynamic and evolving approach in cancer immunotherapy, offering the potential for more effective and personalized treatment options for patients. This review describes significant advancements in therapeutic vaccine strategies that leverage the immune response to target and eliminate cancer cells. The combination of these vaccines with immune checkpoint inhibitors has shown encouraging clinical outcomes, including improved survival rates and tumor reduction across multiple cancer types. This review also addresses key challenges for cancer vaccines such as overall low immunogenicity and tumor heterogeneity, highlighting the potential of combination therapies to overcome these barriers and enhance treatment efficacy.

Keywords

Therapeutic cancer vaccines / Cancer immunotherapy / mRNA and DNA vaccines / Neoantigens / Neoantigens / Medical and Health Sciences / Immunology / Oncology and Carcinogenesis

References

[1] Puig-SausC, et al. . Neoantigen-targeted CD8(+) T cell responses with PD-1 blockade therapy. Nature, 2023, 6157953697-704.

[2] RookG. Tumours and Coley's toxins. Nature, 1992, 3576379545.

[3] LinMJ, et al. . Cancer vaccines: the next immunotherapy frontier. Nat Cancer, 2022, 38911-926.

[4] RezaeiT, et al. . Strategies in DNA vaccine for melanoma cancer. Pigment Cell Melanoma Res, 2021, 345869-891.

[5] KutzlerMA, WeinerDB. DNA vaccines: ready for prime time?. Nat Rev Genet, 2008, 910776-788.

[6] SardesaiNY, WeinerDB. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol, 2011, 233421-429.

[7] PardiN, et al. . mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov, 2018, 174261-279.

[8] BloomK, van den BergF, ArbuthnotP. Self-amplifying RNA vaccines for infectious diseases. Gene Ther, 2021, 283–4117-129.

[9] BeissertT, et al. . A Trans-amplifying RNA Vaccine Strategy for Induction of Potent Protective Immunity. Mol Ther, 2020, 281119-128.

[10] SahinU, et al. . Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature, 2017, 5477662222-226.

[11] HeilF, et al. . Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science, 2004, 30356631526-1529.

[12] NallagatlaSR, et al. . 5'-triphosphate-dependent activation of PKR by RNAs with short stem-loops. Science, 2007, 31858551455-1458.

[13] RingeardM, et al. . FTSJ3 is an RNA 2'-O-methyltransferase recruited by HIV to avoid innate immune sensing. Nature, 2019, 5657740500-504.

[14] HaoP, et al. . mRNA vaccine technology for infectious diseases and beyond. Sci China Life Sci, 2024, 67102267-2270.

[15] YarchoanM, et al. . Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial. Nat Med, 2024, 3041044-1053.

[16] ChandraS, et al. . mRNA vaccines: a new era in vaccine development. Oncol Res, 2024, 32101543-1564.

[17] MehtaA, et al. . Advancements in Melanoma Treatment: A Review of PD-1 Inhibitors, T-VEC, mRNA Vaccines, and Tumor-Infiltrating Lymphocyte Therapy in an Evolving Landscape of Immunotherapy. J Clin Med., 2025, 1441200.

[18] MeliefCJ, et al. . Therapeutic cancer vaccines. J Clin Invest, 2015, 12593401-3412.

[19] BijkerMS, et al. . Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged DC-focused antigen presentation. Eur J Immunol, 2008, 3841033-1042.

[20] BijkerMS, et al. . CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol, 2007, 17985033-5040.

[21] ButterfieldLHCancer vaccines Bmj, 2015, 350: h988

[22] MeliefCJ, van der BurgSH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer, 2008, 85351-360.

[23] HeX, et al. . A Potent Cancer Vaccine Adjuvant System for Particleization of Short, Synthetic CD8(+) T Cell Epitopes. ACS Nano, 2021, 1534357-4371.

[24] MalonisRJ, LaiJR, VergnolleO. Peptide-Based Vaccines: Current Progress and Future Challenges. Chem Rev, 2020, 12063210-3229.

[25] KerrMD, et al. . Combining therapeutic vaccines with chemo- and immunotherapies in the treatment of cancer. Expert Opin Drug Discov, 2021, 16189-99.

[26] MørkSK, et al. . Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma. J Immunother Cancer, 2024, 125e008817.

[27] AhluwaliaMS, et al. . Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma. J Clin Oncol, 2023, 4171453-1465.

[28] SteinmanRM, BanchereauJ. Taking dendritic cells into medicine. Nature, 2007, 4497161419-426.

[29] ChiangCL, BenenciaF, CoukosG. Whole tumor antigen vaccines. Semin Immunol, 2010, 223132-143.

[30] KantoffPW, et al. . Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med, 2010, 3635411-422.

[31] KimVM, et al. . Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies. J Immunother Cancer, 2019, 71132.

[32] HeumannT, et al. . A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma. Nat Commun, 2023, 1413650.

[33] YuZ, et al. . Enhanced nectin-1 expression and herpes oncolytic sensitivity in highly migratory and invasive carcinoma. Clin Cancer Res, 2005, 11134889-4897.

[34] AndersonBD, et al. . High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res, 2004, 64144919-4926.

[35] KaufmanHL, KohlhappFJ, ZlozaA. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov, 2016, 159660.

[36] MorizonoK, et al. . Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat Med, 2005, 113346-352.

[37] GuoP, et al. . ICAM-1 as a molecular target for triple negative breast cancer. Proc Natl Acad Sci U S A, 2014, 1114114710-14715.

[38] ShafrenDR, et al. . Oncolysis of human ovarian cancers by echovirus type 1. Int J Cancer, 2005, 1152320-328.

[39] CarlstenM, et al. . Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J Immunol, 2009, 18384921-4930.

[40] KanervaA, et al. . Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin Cancer Res, 2013, 19102734-2744.

[41] LiX, et al. . Viral Vector-Based Gene Therapy. Int J Mol Sci., 2023, 2497736.

[42] Robert-GuroffM. Replicating and non-replicating viral vectors for vaccine development. Curr Opin Biotechnol, 2007, 186546-556.

[43] InnaoV, et al. . Oncolytic Viruses and Hematological Malignancies: A New Class of Immunotherapy Drugs. Curr Oncol, 2020, 281159-183.

[44] RehmanH, et al. . Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J Immunother Cancer, 2016, 4: 53.

[45] PalmerCD, et al. . Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med, 2022, 2881619-1629.

[46] KeskinDB, et al. . Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature, 2019, 5657738234-239.

[47] NielsenM, et al. . Immunoinformatics: Predicting Peptide-MHC Binding. Annu Rev Biomed Data Sci, 2020, 3: 191-215.

[48] ThomasS, et al. . Artificial Intelligence in Vaccine and Drug Design. Methods Mol Biol, 2022, 2410: 131-146.

[49] ZhaoX, ZhaoR, NieG. Nanocarriers based on bacterial membrane materials for cancer vaccine delivery. Nat Protoc, 2022, 17102240-2274.

[50] KulkarniJA, CullisPR, van der MeelR. Lipid Nanoparticles Enabling Gene Therapies: From Concepts to Clinical Utility. Nucleic Acid Ther, 2018, 283146-157.

[51] PatelS, et al. . Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA. Nat Commun, 2020, 111983.

[52] ChengQ, et al. . Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol, 2020, 154313-320.

[53] TaiW, et al. . A lung-selective delivery of mRNA encoding broadly neutralizing antibody against SARS-CoV-2 infection. Nat Commun, 2023, 1418042.

[54] GuZ, et al. . Liposome-Based Drug Delivery Systems in Cancer Immunotherapy. Pharmaceutics., 2020, 12111054.

[55] Zhong R, et al. Hydrogels for RNA delivery. Nat Mater, 2023;22(7):818–31.

[56] DingJ, et al. . Chiral polypeptide hydrogels regulating local immune microenvironment and anti-tumor immune response. Nat Commun, 2025, 1611222.

[57] SeclìL, et al. . Personalized Cancer Vaccines Go Viral: Viral Vectors in the Era of Personalized Immunotherapy of Cancer. Int J Mol Sci, 2023, 242316591.

[58] YinD, et al. . Dendritic-cell-targeting virus-like particles as potent mRNA vaccine carriers. Nat Biomed Eng, 2025, 92185-200.

[59] GuoX, et al. . The interplay between the tumor microenvironment and tumor-derived small extracellular vesicles in cancer development and therapeutic response. Cancer Biol Ther, 2024, 2512356831.

[60] OttPA, et al. . An immunogenic personal neoantigen vaccine for patients with melanoma. Nature, 2017, 5477662217-221.

[61] MoynihanKD, et al. . Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med, 2016, 22121402-1410.

[62] RosenbergSA, RestifoNP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science, 2015, 348623062-68.

[63] MerloLM, et al. . Cancer as an evolutionary and ecological process. Nat Rev Cancer, 2006, 612924-935.

[64] TangH, et al. . Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade. Cancer Cell, 2016, 293285-296.

[65] LiYR, et al. . Boosting CAR-T cell therapy through vaccine synergy. Trends Pharmacol Sci, 2025, 462180-199.

[66] ChowellD, et al. . Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science, 2018, 3596375582-587.

[67] SinghaviranonS, et al. . Low-avidity T cells drive endogenous tumor immunity in mice and humans. Nat Immunol, 2025, 262240-251.

[68] JardimDL, et al. . The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell, 2021, 392154-173.

Funding

the National Science and Technology Major Project of China(2023ZD0502401)

the National Natural Science Foundation of China(32270695)

RIGHTS & PERMISSIONS

The Author(s)